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IntroductIon
Lung cancer is one of the most frequently diagnosed tumors in Italy (11% of total tumors, 
excluding skin carcinomas) and, by far, one of the main causes of oncologic death (26% in 
males and 11% in females) [1]. The high mortality compared to other tumors is partly due to 
the delay in the diagnosis. In fact, since the first stages of lung cancer show no symptoms, 
or show non-specific symptoms, at the time of diagnosis most patients present a locally ad-
vanced or metastatic disease [2].
AbstrAct
BACKGROUND: A histopathological and mutational diagnosis has become a priority in the correct choice of the most 
appropriate cancer therapy for NSCLC. In the absence of a molecular analysis, the therapeutic choice will be directed to-
wards platinum-based chemotherapy, thus preventing, in the presence of a specific mutation, the benefits deriving from the 
administration of a target therapies (TT).
AIM: the present analysis was carried out with the aim of estimating the clinical impact, expressed in terms of progression 
free survival (PFS), associated with the use of the combined strategy (tissue biopsy and liquid biopsy) or the tissue strategy 
in the EGFR+ mNSCLC population.
METHODS: A pre-existing cost-consequence model was adapted to estimate the annual number of mNSCLC patients with 
or without the EGFR mutation in order to decide the oncological treatment to be administered in first (1L) or second line 
(2L). In 1L, against the presence of the EGFR mutation, the administration of a Tyrosine Kinase Inhibitor (TKI), such as 
osimertinib, gefitinib, erlotinib or afatinib, was considered; in the absence of the EGFR mutation, the administration of 
standard platinum-based chemotherapy was instead considered. With reference to 2L, in the presence of the EGFR T790M 
mutation, only osimertinib was considered. In the absence of the EGFR T790M mutation, the administration of the stan-
dard platinum-based chemotherapy was also considered. The PFS data associated with each of the drugs considered were 
extrapolated from the respective clinical studies. Key variables were tested in the sensitivity analysis.
RESULTS: The adoption of the combined strategy (tissue biopsy and liquid biopsy), by virtue of a greater number of pa-
tients treated with TKIs, would make it possible to increase the average PFS in the range of 1.1-3,7 months in the 1L and 
by 1.4 months in the 2L.
CONCLUSION: These results show how the adoption of a correct diagnostic strategy is critical in order to optimize the 
choice of the therapeutic path in the 1L and 2L of mNSCLC. The addition of the liquid biopsy to the classic diagnostic path 
(tissue biopsy) would in fact allow to obtain an increase in therapeutic efficacy (average PFS). 
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Lung cancer is clinically differentiated in two types: Small-Cell Lung Cancer (SCLC, 
15% of cases) and Non-Small Cell Lung Cancer (NSCLC, 85% of cases) [3]. 
In recent years, the diagnostic approach to lung cancer has changed radically, requiring – 
in addition to the conventional histopathological diagnosis – the molecular characterization 
of the tumor (eg. EGFR – Epidermal Growth Factor Receptor, and ALK – Anaplastic Lym-
phoma Kinase mutations) and some predictors of the response to immunotherapy (eg. PDL1) 
[4]. Therefore, a histopathological and mutational diagnosis becomes a priority in the correct 
choice of the most appropriate cancer therapy, especially in the face of a growing availability 
of target therapies (TT) [5-7]. In the absence of a molecular analysis, the therapeutic choice 
will in fact be directed towards platinum-based chemotherapy, thus preventing, in the pres-
ence of a specific mutation, the benefits deriving from the administration of a TT [5].
A previous analysis [8], which should be referred to for more details, evaluated the eco-
nomic impact on the Italian National Health Service (NHS) determined by the adoption of dif-
ferent diagnostic strategies that involved the use of tissue biopsy, alone or in combination with 
the liquid one, to identify the presence of a sensitizing and/or resistance EGFR mutation in the 
first- and second-line treatment of locally advanced or metastatic non-small cell carcinoma 
(mNSCLC). The results of the analysis showed that the diagnostic approach characterized by 
the use of the tissue biopsy alone (tissue strategy) was not cost effective, unlike the one that 
involved the addition of the liquid biopsy (combined strategy) which, by allowing instead the 
correct identification of a greater number and type of EGFR mutations, resulted in a lower 
average cost per correctly identified case. 
Based on these previous results – which indirectly also guide the prescription of the best 
oncological treatment based on the correctly identified mutations – the present analysis was 
carried out with the aim of estimating the clinical impact, expressed in terms of progression 
free survival (PFS), associated with the use of the combined strategy (tissue biopsy and liquid 
biopsy) or the tissue strategy in the EGFR+ mNSCLC population.
Methods
Model structure
A pre-existing Cost-Consequence Model (CCM) was adapted to estimate the annual num-
ber of patients with mNSCLC that could be tested for the identification of the EGFR muta-
tion in order to decide the oncological therapy to be administered in first or second line [8]. 
Specifically, it was verified whether, compared to tissue biopsy alone, the combined strategy 
could determine – thanks to a greater number of correctly identified EGFR cases, and there-
fore to a more targeted oncologic therapy – an increase in PFS among mNSCLC patients 
starting first- or second-line treatment.
Of the original CCM, two diagnostic options were considered, one characterized by the 
use of tissue biopsy alone (tissue strategy), and the other by the combined use of tissue and 
liquid biopsy (combined strategy). The tissue strategy (Figure 1), which is mainly the standard 
of care [8], involves performing only a tissue biopsy for all patients eligible for the diagnostic 
investigation and for the first-line treatment (1L); for the other patients (i.e. poor performance 
status) – eligible for 1L, but not for tissue biopsy – no further diagnostic procedure is pro-
vided for. In case of disease progression (second-line treatment – 2L), the strategy involves 
performing a second tissue biopsy for all patients eligible for tissue re-biopsy and 2L. For the 
other patients eligible for 2L, but not for tissue re-biopsy, no biopsy is provided. The com-
bined strategy (Figure 1) involves the execution of a tissue biopsy in all patients eligible for 
the diagnostic investigation and for 1L; for all cases where it was not possible to determine 
the outcome after the first tissue biopsy, a liquid biopsy is performed (unlike in the tissue 
strategy). For the patients eligible for 1L but not for tissue biopsy, no further biopsy proce-
dure is envisaged. Unlike the tissue strategy, in case of disease progression, a liquid biopsy 
is provided for all patients eligible to receive 2L. Following a negative outcome of the liquid 
biopsy in determining the EGFR T790M mutation, a subsequent tissue biopsy is performed.
Population
The first step of the analysis involved the estimation of the number of patients eligible for 
the diagnostic strategy (tissue or combined) for the identification of the EGFR mutation (Ta-
ble I). The estimate was made starting from the number of new cases of lung cancer estimated 
for 2018 in Italy [1]. From these, the cases of NSCLC [3] were first calculated, and then those 
with a diagnosis of adenocarcinoma, squamous cell carcinoma or large-cell carcinoma were 
identified [9]. Only the cases of the subjects with a diagnosis of mNSCLC [10] eligible for 
1L were then considered [3]. It is estimated that 85% of these patients are eligible for tissue 
biopsy [11]. Among patients performing tissue biopsy, the outcome may not be determinable 
in 30% of cases [12]. Finally, 40% of patients with a diagnosis of mNSCLC are eligible to 
receive 2L [3]; of these, 82% are eligible for tissue re-biopsy [5] and 100% for liquid biopsy. 
Based on the literature data, an expected prevalence of the EGFR mutation of 18.9% and 
an expected prevalence of the EGFR T790M 
mutation of 63.2% were considered for the 
first-line treatment [3] and for the second-line 
treatment [13], respectively.
Performance data
Table II shows the sensitivity and speci-
ficity percentages associated with the diag-
nostic test (cobas® EGFR Mutation Test v2, 
Roche Molecular Systems, Inc.) performed 
on tissue samples (tissue biopsy) or plasma 
(liquid biopsy) for the identification of the 
EGFR mutation [14,15]. The hypothesis un-Figure 1. Diagnostic strategies compared in the analysis
Parameters Population (n) Source
New cases of lung cancer 41,500 [1]
Patients with NSCLC (83.0%) 34,445 [3]
Patients with adenocarcinoma, squamous cell carcinoma or large cell carcinoma (67.0%) 23,078 [9]
Patients with locally advanced disease or metastasis at diagnosis (74.1%) 17,101 [10]
First-line treatment
Patients eligible for the first-line treatment (89.0%) 15,220 [3]
Patients eligible for the tissue biopsy (85.0%) 12,937 [11]
 • determinable outcome after tissue biopsy (70.0%) 9,056 Calculated from [12]
 • non-determinable outcome after tissue biopsy (30,0%) 3,881 [12]
Patients not eligible for tissue biopsy, but eligible for liquid biopsy (15.0%) 2,283 Calculated from [11]
Second-line treatment
Patients eligible for the second-line treatment (40.0%) 6,840 [3]
Patients eligible for the second tissue biopsy (82.0%) 5,609 [5]
Patients eligible for the liquid biopsy (100.0%) 6,840 Assumption
Prevalence of the EGFR mutation
EGFR+ – first-line treatment 18.9% [3]
EGFR+ – second-line treatment 63.2% [13]
Table I. Population included in the CCM
EGFR mutations Liquid biopsy Tissue biopsy
First-line treatment1
Sensitivity (%) 95.0 98.1
Specificity (%) 91.0 99.3
Second-line treatment2
Sensitivity (%) 93.0 90.0
Specificity (%) 92.0 98.0
Table II. Sensitivity and specificity associated with the cobas® EGFR Mutation 
Test [14,15]
1 Exons 19, 21
2 T790M
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status) – eligible for 1L, but not for tissue biopsy – no further diagnostic procedure is pro-
vided for. In case of disease progression (second-line treatment – 2L), the strategy involves 
performing a second tissue biopsy for all patients eligible for tissue re-biopsy and 2L. For the 
other patients eligible for 2L, but not for tissue re-biopsy, no biopsy is provided. The com-
bined strategy (Figure 1) involves the execution of a tissue biopsy in all patients eligible for 
the diagnostic investigation and for 1L; for all cases where it was not possible to determine 
the outcome after the first tissue biopsy, a liquid biopsy is performed (unlike in the tissue 
strategy). For the patients eligible for 1L but not for tissue biopsy, no further biopsy proce-
dure is envisaged. Unlike the tissue strategy, in case of disease progression, a liquid biopsy 
is provided for all patients eligible to receive 2L. Following a negative outcome of the liquid 
biopsy in determining the EGFR T790M mutation, a subsequent tissue biopsy is performed.
Population
The first step of the analysis involved the estimation of the number of patients eligible for 
the diagnostic strategy (tissue or combined) for the identification of the EGFR mutation (Ta-
ble I). The estimate was made starting from the number of new cases of lung cancer estimated 
for 2018 in Italy [1]. From these, the cases of NSCLC [3] were first calculated, and then those 
with a diagnosis of adenocarcinoma, squamous cell carcinoma or large-cell carcinoma were 
identified [9]. Only the cases of the subjects with a diagnosis of mNSCLC [10] eligible for 
1L were then considered [3]. It is estimated that 85% of these patients are eligible for tissue 
biopsy [11]. Among patients performing tissue biopsy, the outcome may not be determinable 
in 30% of cases [12]. Finally, 40% of patients with a diagnosis of mNSCLC are eligible to 
receive 2L [3]; of these, 82% are eligible for tissue re-biopsy [5] and 100% for liquid biopsy. 
Based on the literature data, an expected prevalence of the EGFR mutation of 18.9% and 
an expected prevalence of the EGFR T790M 
mutation of 63.2% were considered for the 
first-line treatment [3] and for the second-line 
treatment [13], respectively.
Performance data
Table II shows the sensitivity and speci-
ficity percentages associated with the diag-
nostic test (cobas® EGFR Mutation Test v2, 
Roche Molecular Systems, Inc.) performed 
on tissue samples (tissue biopsy) or plasma 
(liquid biopsy) for the identification of the 
EGFR mutation [14,15]. The hypothesis un-Figure 1. Diagnostic strategies compared in the analysis
Parameters Population (n) Source
New cases of lung cancer 41,500 [1]
Patients with NSCLC (83.0%) 34,445 [3]
Patients with adenocarcinoma, squamous cell carcinoma or large cell carcinoma (67.0%) 23,078 [9]
Patients with locally advanced disease or metastasis at diagnosis (74.1%) 17,101 [10]
First-line treatment
Patients eligible for the first-line treatment (89.0%) 15,220 [3]
Patients eligible for the tissue biopsy (85.0%) 12,937 [11]
 • determinable outcome after tissue biopsy (70.0%) 9,056 Calculated from [12]
 • non-determinable outcome after tissue biopsy (30,0%) 3,881 [12]
Patients not eligible for tissue biopsy, but eligible for liquid biopsy (15.0%) 2,283 Calculated from [11]
Second-line treatment
Patients eligible for the second-line treatment (40.0%) 6,840 [3]
Patients eligible for the second tissue biopsy (82.0%) 5,609 [5]
Patients eligible for the liquid biopsy (100.0%) 6,840 Assumption
Prevalence of the EGFR mutation
EGFR+ – first-line treatment 18.9% [3]
EGFR+ – second-line treatment 63.2% [13]
Table I. Population included in the CCM
EGFR mutations Liquid biopsy Tissue biopsy
First-line treatment1
Sensitivity (%) 95.0 98.1
Specificity (%) 91.0 99.3
Second-line treatment2
Sensitivity (%) 93.0 90.0
Specificity (%) 92.0 98.0
Table II. Sensitivity and specificity associated with the cobas® EGFR Mutation 
Test [14,15]
1 Exons 19, 21
2 T790M
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derlying the comparison between the two therapeutic strategies is represented by the fact that, 
by ensuring a greater diagnostic accuracy, the addition of the liquid biopsy makes it possible 
to identify more frequently the most effective cancer treatment.
Clinical data
The model, as already mentioned, aimed to estimate the Progression-Free Survival (PFS) of 
mNSCLC patients on the basis of the diagnostic strategy adopted. Following the AIOM guide-
lines [16], Table III reports the details of the first- and second-line PFS associated with the cancer 
therapies currently reimbursed in Italy for the management of mNSCLC patients with or without 
EGFR mutation. In 1L, against the presence of the EGFR mutation, the administration of a Tyro-
sine Kinase Inhibitor (TKI), such as osimertinib, gefitinib, erlotinib or afatinib, was considered; 
in the absence of the EGFR mutation, the administration of standard platinum-based chemo-
therapy was instead considered. With reference to 2L, in the presence of the EGFR T790M muta-
tion, only osimertinib was considered, in the hypothesis, however, that in the previous first-line 
treatment only one drug, among gefitinib, erlotinib or afatinib, had been administered. In the 
absence of the EGFR T790M mutation, the administration of the standard platinum-based che-
motherapy was also considered. The PFS data associated with each of the drugs considered were 
extrapolated from the respective clinical studies [17-27]. In 1L, the PFS with gefitinib, erlotinib 
or afatinib was calculated as a weighted average based on the patients enrolled in the respective 
clinical studies [18-26], while for osimertinib the PFS was taken from the FLAURA [17] and 
AURA3 studies [27], for the first- and second-line treatment, respectively. In comparison with 
gefitinib, erlotinib and afatinib, the PFS of standard platinum-based chemotherapy in 1L was also 
calculated as a weighted average (number of patients enrolled) of the respective clinical studies 
[18-26]. Differently, in the comparison with osimertinib in 1L, not having the FLAURA study 
[17] estimated a specific data, the PFS associated with the standard platinum-based chemothera-
py was calculated as a weighted average (number of patients enrolled) of the PFSs estimated for 
the chemotherapies considered in the clinical studies conducted with gefitinib, erlotinib and afa-
tinib [18-26]. In 2L, the PFS of osimertinib was compared with that associated with the standard 
platinum-based chemotherapy, based on the results of the AURA3 study [27].
Model output data
Based on the number of correctly diagnosed EGFR+ mNSCLC patients, the analysis pro-
vided for the two diagnostic strategies, and along a time horizon of one year, the number of 
patients eligible for treatment (1L and 2L) with TKIs or with platinum-based chemotherapy, 
and the corresponding difference expressed in terms of average PFS. Specifically, the follow-
ing comparisons were conducted:
 - 1L
 - Osimertinib vs platinum-based chemotherapy
 - Gefitinib vs platinum-based chemotherapy
 - Erlotinib vs platinum-based chemotherapy
 - Afatinib vs platinum-based chemotherapy
Indication Drug PFS (months) Source
First-line treatment
EGFR+ Osimertinib 18.9 FLAURA [17]
Gefitinib 10.1 IPASS [18], First-SIGNAL [19], WJTOG 3405 [20], 
NEJGSG002 [21], LUX-Lung 7 [22]
Erlotinib 11.3 OPTIMAL [23], EURTAC [24]
Afatinib 11.0 LUX-Lung 3 [25], LUX-Lung 6 [26], LUX-Lung 7 [22]
EGFR- Chemotherapy vs gefitinib 6.1 IPASS [18], First-SIGNAL [19], WJTOG 3405 [20], 
NEJGSG002 [21], LUX-Lung 7 [22]
Chemotherapy vs erlotinib 4.9 OPTIMAL [23], EURTAC [24]
Chemotherapy vs afatinib 6.2 LUX-Lung 3 [25], LUX-Lung 6 [26], LUX-Lung 7 [22]
 Chemotherapy 5.9 Weighted average
Second-line treatment
EGFR+ Osimertinib 10.1 AURA3 [27]
EGFR- Chemotherapy 4.4 AURA3 [27]
Table III. Assumptions for the first- and second-line PFS associated with the treatments considered
5Farmeconomia. Health economics and therapeutic pathways 2020; 21(1)
G. Gancitano, R. Ravasio, L. Cattelino, P. Di Procolo, M. Dionisi, D. Cortinovis
 - 2L
 - Osimertinib vs platinum-based chemotherapy
Sensitivity analysis
The sensitivity analysis was carried out on the parameters most able to affect the results 
of the base case [28].
With respect to the epidemiological context outlined in the base case, a reduction in the 
percentage of cases with a non-determinable outcome after the first tissue biopsy was con-
sidered, effectively halving – from 30 to 15% – the probability for patients subsequently 
subjected to liquid biopsy.
The second parameter, instead, investigated the sensitivity and specificity of the test used 
to determine the EGFR mutation in the liquid biopsy. In particular, with respect to the base 
case, the sensitivity and specificity of the test were varied, considering simultaneously (multi-
variate analysis) the respective lower extremes of the Confidence Interval [15], leaving how-
ever unchanged the values  of sensitivity and specificity associated with the test for the tissue 
biopsy. 
results
With reference to 1L, the model considered a total of 12,937 mNSCLC patients eligible 
for the diagnostic investigation (tissue or combined strategy), 2,445 of whom were expected 
to be EGFR+ (Table IV) [3].
In 2L, eligible mNSCLC patients were instead 6,840, 4,325 of whom were expected to be 
EGFR T790M+ (Table V) [13]. As an alternative to the tissue strategy, the combined strategy 
would allow to increase the number of EGFR+ patients correctly diagnosed both in the first 
(+679) (Table IV) and the second (+1,054) line of treatment (Table V).
The identification of a greater number of EGFR+ patients would lead to an improvement 
in the clinical benefits expressed in terms of PFS, by virtue of the greater number of patients 
treated with TKIs. Tables IV and V show, for each of the pharmacological comparisons con-
sidered, the average increases in PFS per patient treated, thus favoring the adoption of the 
combined strategy over the tissue one. 
In 1L (Table IV), if osimertinib is used, the average increase in PFS would be 3.7 months 
(from the 14.8 months of the tissue strategy to the 18.5 months of the combined strategy). 
While considering the administration of the other three TKIs, the average increase in PFS 
would be in the range of 1.1-1.8 months.
First-line treatment Combined strategy Tissue strategy
Δ PFS
(months)
Eligible patients (n) 12,937 12,937
Patients (n) PFS (months) Patients (n) PFS (months)
Osimertinib vs chemotherapy
Expected EGFR+ 2,445 185 2,445 14.8 3.7
EGFR+ correctly identified 2,376 18.9 1,679 18.9
EGFR+ not correctly identified 69 5.9 766 5.9
Gefitinib vs chemotherapy
Expected EGFR+ 2,445 10.0 2,445 8.8 1.1
EGFR+ correctly identified 2,376 10.1 1,679 10.1
EGFR+ not correctly identified 69 6.1 766 6.1
Erlotinib vs chemotherapy
Expected EGFR+ 2,445 11.1 2,445 9.3 1.8
EGFR+ correctly identified 2,376 11.3 1,679 11.3
EGFR+ not correctly identified 69 4.9 766 4.9
Afatinib vs chemotherapy
Expected EGFR+ 2,445 10.9 2,445 9.5 1.4
EGFR+ correctly identified 2,376 11.0 1,679 11.0
EGFR+ not correctly identified 69 6,2 766 6.2  
Table IV. Results – first-line treatment
6 Farmeconomia. Health economics and therapeutic pathways 2020; 21(1)
Clinical Impact of two Different Diagnostic Strategies in the First- and Second-Line Treatment of Locally Advanced
With reference to 2L (Table V), the adoption of the combined strategy, once again by 
virtue of a greater number of patients treated with TKI (osimertinib), would make it possible 
to increase the average PFS by 1.4 months, from 8.6 months (tissue strategy) to 10.0 months 
(combined strategy).
Sensitivity analysis
Table VI reports the results of the sensitivity analysis, expressed in terms of average PFS 
for each diagnostic strategy adopted. All comparisons confirm the greater clinical effect (in-
crease in average PFS) associated with the combined strategy. Among the two parameters 
considered, the reduction in the probability that a first-line patient may have a tissue biopsy 
with a non-determined outcome is the one that mostly affects the results of the comparison 
between tissue and combined strategy, significantly reducing the difference in the average 
PFS between the two strategies diagnostic compared to the base case.
dIscussIon
The diagnostic/therapeutic approach to NSCLC requires the integration of histopathologi-
cal diagnosis and molecular characterization of the tumor. In the absence of the molecular 
analysis, the therapeutic choice will be directed towards platinum-based chemotherapy, pre-
cluding the patient, in case of EGFR mutation, from the benefits deriving from the administra-
tion (in first and second line) of a targeted therapy (eg. TKIs).
Unlike the tissue biopsy, the liquid biopsy is a low-invasiveness diagnostic method for 
the evaluation of possible tumor mutations based on the analysis of free circulating DNA 
(cfDNA) present in the plasma component of the blood [29]. Since blood samples are easily 
obtained, plasma biopsy is a non-invasive method to supplement traditional biopsy techniques 
and, in addition, in the advanced therapy lines, it can dynamically evaluate the presence of the 
most common resistance mechanism to first- and second-generation inhibitors, such as EGFR 
T790M resistance mutation.
The present analysis evaluated the clinical impact – measured in terms of months free 
from disease progression – achieved through the adoption of two different diagnostic strate-
Second-line treatment Combined strategy Tissue strategy
Δ PFS
(months)
Eligible patients (n) 6,840 6,840  
Osimertinib vs chemotherapy Patients (n) PFS (months) Patients (n) PFS (months)
Expected EGFR T790M+ 4,325 10.0 4,325 8.6 1.4
EGFR T790M+ correctly identified 4,246 10.1 3,192 10.1
EGFR T790M+ not correctly identified 79 4.4 1,133 4.4  
Table V. Results – second-line treatment
Parameters
Combined strategy  
(mean PFS)
Tissue strategy 
(mean PFS)
Difference  
(mean PFS)
Cases with a non-determinable outcome after the first tissue biopsy (15%)
Osimertinib vs chemotherapy (1L) 18.6 16.7 1.8
Gefitinib vs chemotherapy (1L) 10.0 9.4 0.6
Erlotinib vs chemotherapy (1L) 11.1 10.2 0.9
Afatinib vs chemotherapy (1L) 10.9 10.2 0.7
Osimertinib vs chemotherapy (2L) 10.0 8.6 1.4
Lower extremes of the CI (liquid biopsy sensitivity and specificity)
Osimertinib vs chemotherapy (1L) 18.4 14.8 3.6
Gefitinib vs chemotherapy (1L) 9.9 8.8 1.1
Erlotinib vs chemotherapy (1L) 11.1 9.3 1.8
Afatinib vs chemotherapy (1L) 10.9 9.5 1.3
Osimertinib vs chemotherapy (2L) 9.9 8.6 1.3
Table VI. Results – sensitivity analysis
CI = confidence interval
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gies aimed at determining the EGFR mutation in mNSCLC patients in the first or second line 
of treatment. The combined approach, which involves the use of the liquid biopsy in addition 
to the tissue biopsy, allowed – compared to the use of the tissue biopsy alone (tissue strategy) 
– to identify a greater number of EFGR+ mNSCLC patients. This result, thanks to the pos-
sibility of treating a greater number of patients with TKIs, would lead to an increase in the 
average PFS of EFGR+ mNSCLC patients, depending on the specific TKI administered (1L 
PFS: 1.1-3.7 months; 2L PFS: 1.4 months).
The results of the present analysis should be read in the light of some observations. The 
structure of the simulation model adopted here certainly represents a simplification of the cur-
rent diagnostic-therapeutic pathway for NSCLC, since it is characterized by multiple options 
and decisions guided by several factors (patient’s age, performance status, tolerability, etc.). 
Despite this, the model has nevertheless considered the treatment options most widely used 
according to the level of the disease and the treatment lines [16].
The epidemiological analysis was carried out in order to define, starting from a common 
sample base (number of new cases of lung cancer), the number of patients eligible for the 
two diagnostic strategies investigated. This process was conducted using data from different 
bibliographic sources and, in the absence thereof, by making some assumptions. To limit the 
uncertainty associated with this process, a sensitivity analysis was carried out on the epide-
miological variable that could most affect the outcome of the base case: the probability that a 
patient in 1L may have a tissue biopsy with a non-determined outcome. The reduction of this 
probability from 30% to 15%, despite not contradicting the results of the base case, would 
significantly reduce the differential expressed in terms of PFS, to the advantage of the com-
bined strategy.
The sensitivity analysis conducted on the sensitivity and specificity of the test used to 
identify the EGFR mutation (cobas® EGFR Mutation Test v2) largely confirmed the results 
of the base case.
A further observation also concerns the fact that this model evaluates in particular the 
hypothesis of a sequential therapeutic strategy with TK inhibitors in relation to the possible 
appearance of resistance mutation; however, the methodology described can be used in all 
cases where it is necessary or desirable to perform a biomolecular in-depth analysis in an 
oncogene-addicted tumor upon the diagnosis and the progression of the disease.
Since they were not present in the literature, it was not possible to compare these results 
with those of other evaluations, with the sole exception of those of a recent study conducted 
on the determination of the ALK mutation in NSCLC patients [30]. According to the authors, 
a greater use of a specific immunohistochemical test (Ventana®), compared to other tests and 
FISH, would allow to increase the correct identification of the ALK+ mutation, with a conse-
quent increase in the overall survival from 27.1 months to 32.4 months.  
Furthermore, in terms of new diagnostic approaches, liquid biopsy, by allowing the detec-
tion of circulating free DNA (cfDNA), paves the way to the use of Next Generation Sequenc-
ing (NGS) methodologies, a technique characterized by the possibility of sequencing DNA 
molecules simultaneously, which allows to identify, in a single analysis: mutations, variations 
in the number of gene copies, fusions and gene expression. Through the use of NGS panels, a 
better interpretation of possibly negative investigations for mutations driver of interest is pos-
sible. In fact, the identification of at least one gene variant in the liquid biopsy is the proof of 
the presence of circulating tumor DNA (ctDNA), and allows to report with greater confidence 
a negative result for the mutation of interest [31].
Finally, it is emphasized that the present analysis just evaluated the clinical consequences 
deriving from the choice of one of the two different diagnostic strategies, measured in terms 
of average PFS, net of the economic consequences (treatment cost) which this choice could 
involve.
conclusIons
The possibility to carry out a molecular analysis every time it is necessary, regardless 
of the patient’s performance status, makes it possible to identify the most appropriate can-
cer therapy, maximizing the effectiveness of the treatment path and minimizing the waste 
of health resources. The results found here show how the adoption of a correct diagnostic 
strategy is critical in order to optimize the choice of the therapeutic path in the first- and 
second-line treatment of mNSCLC. The addition of the liquid biopsy to the classic diag-
nostic path (tissue biopsy) would in fact allow to obtain an increase in therapeutic efficacy 
(average PFS).
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